Jointechlabs
Jointechlabs: Global leader in cost-effective, non-surgical regenerative medicine therapies.
Founded
2014Jointechlabs: Global leader in cost-effective, non-surgical regenerative medicine therapies.
Jointechlabs is a global leader in point-of-care regenerative medicine therapies, focusing on non-surgical solutions. Their flagship products include the FDA-cleared MiniTC® Adipose Processing System, which processes autologous fat into purified microfat for injection, and the CE-Mark pending Mini-Stem System® for stromal vascular fraction (SVF) processing outside the USA. These innovations enable healthcare practitioners and hospitals to offer safe, cost-effective regenerative treatments directly at the point of care.
Jointechlabs has made significant strides in the field of regenerative medicine, earning FDA clearance for their MiniTC® device and pending CE-Mark approval for their Mini-Stem System®. Their technology has been recognized for its ability to provide high-quality, non-surgical treatment options, enhancing patient outcomes and reducing healthcare costs. The company's impact is evident in its growing adoption by healthcare providers worldwide, positioning Jointechlabs as a pioneering force in regenerative medicine.
Companies similar to Jointechlabs include Syntr Health Technologies, Biosculpture Technology, EndoCellutions and Juvent - Regenerative Technologies.
Jointechlabs was founded in 2014.
Jointechlabs' headquarters is located in Chicago, IL, US.
Jointechlabs' most recent funding round was for $250k (USD) in October 2022.
As of Oct 7, 2022, Jointechlabs has disclosed funding of $2M (USD). Undisclosed round amounts are excluded.
Jointechlabs has 6 employees as of Feb 4, 2024.
Juvent - Regenerative Technologies
juvent.com
